381
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Comparing cigarette-cue attentional bias between people with HIV/AIDS and people with opioid use disorder who smoke

, , , &
Article: 2255028 | Received 31 Aug 2022, Accepted 28 Aug 2023, Published online: 07 Sep 2023
 

ABSTRACT

Background

Special populations like people living with HIV/AIDS (PLWHA) and people with opioid use disorder (OUD) smoke tobacco cigarettes at rates three to four times greater than the general population. Patients with tobacco use disorder exhibit attentional bias (AB) for cigarette cues. Eye tracking can quantify this bias by measuring fixation time (FT) on cigarette and matched neutral cues, to calculate an AB score. Although previous studies have measured this bias in people who smoke without any other comorbid conditions, no study, to our knowledge, has measured or compared this bias in special populations.

Methods

We performed exploratory analyses on eye tracking data collected in two separate randomized clinical trials (RCTs) (NCT05049460, NCT05295953). We compared FT and cigarette-cue AB score (measured by subtracting FT on neutral cues from FT on cigarette cues) between PLWHA and people with OUD who smoke, using a visual probe task and Tobii Pro Fusion eye tracker. We used two cigarette cue types, one encompassing people smoking cigarettes and the other consisting of cigarette paraphernalia. We used two cue presentation times, 1000 and 2000 milliseconds (ms).

Results

Cues of people smoking cigarettes elicited greater AB than cues of cigarette paraphernalia across both subject groups when cues were presented for 2000 ms, but not 1000 ms. PLWHA who smoke exhibited greater AB for cues of people smoking cigarettes than cigarette paraphernalia when presented for 2000 ms compared to people with OUD who smoke.

Conclusion

We use cigarette-cue AB to quantify craving and cigarette consumption in two populations smoking at elevated rates. The addition of social cues potentiates cigarette cue AB, based on cue type and stimulus presentation time. Understanding the neurobiology of this relationship can help design novel smoking cessation treatments that target AB and prevent relapse in these populations with suboptimal response to smoking cessation treatments.

Trial registration

Clinical trials that provided the data for post hoc analyses are NCT05049460 and NCT05295953.

Acknowledgements

We thank Madona Elias, MSW who assisted with data collection and Christopher McLouth, PhD who reviewed the statistical analyses in the manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

Our study data is available on Mendeley Data. The DOI is http://dx.doi.org/10.17632/g6yzzr34sx.1

Additional information

Funding

This work was supported by the National Institutes of Health (grant numbers CA225419, DA035200) and by the Junior Scholars' Research Award from the University of Kentucky Department of Psychiatry.